CrossrefInfokarte
Neoadjuvant Cytoreductive Treatment of Regionally Advanced Melanoma With BRAF/MEK Inhibition: Study Protocol of the REDUCTOR (Cytoreductive Treatment of Dabrafenib Combined With Trametinib to Allow Complete Surgical Resection in Patients With BRAF Mutated, Prior Unresectable Stage III or IV Melanoma) Trial
Clinical Skin Cancer · 2016
DOI: 10.1016/j.clsc.2016.11.006 ↗Abstract
Kein Abstract verfügbar.
EUVIMED